Coherus Oncology (CHRS) Depreciation & Amortization (CF) (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $881000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 15.77% year-over-year to $881000.0; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (down 21.93% YoY), and the FY2025 full-year result was $3.9 million, down 25.63% from the prior year.
• Depreciation & Amortization (CF) slipped to $881000.0 in Q1 2026, from $896000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.5 million in Q3 2024 to a low of $767000.0 in Q1 2022.
• A 5-year average of $1.0 million and a median of $966000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) soared 72.3% in 2024 and plunged 37.64% in 2025, its largest moves.
• Tracing CHRS's Depreciation & Amortization (CF) over 5 years: stood at $1.0 million in 2022, then increased by 1.24% to $1.1 million in 2023, then retreated by 2.82% to $1.0 million in 2024, then dropped by 13.26% to $896000.0 in 2025, then dropped by 1.67% to $881000.0 in 2026.
• Business Quant data shows CHRS's Depreciation & Amortization (CF) at $881000.0 in Q1 2026, $896000.0 in Q4 2025, and $966000.0 in Q3 2025.